DELORAZEPAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H10Cl2N2O
Molecular Weight	305.159
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC2=C(NC(=O)CN=C2C3=C(Cl)C=CC=C3)C=C1

InChI

InChIKey=CHIFCDOIPRCHCF-UHFFFAOYSA-N

InChI=1S/C15H10Cl2N2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

HIDE SMILES / InChI

Molecular Formula	C15H10Cl2N2O
Molecular Weight	305.159
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.nutrizioneesalute.it/farmaci/en-delorazepam | https://www.codifa.it/farmaci/e/en-compressa-gocce-delorazepam-ansiolitici-benzodiazepinici | https://www.caymanchem.com/product/15938

Delorazepam is a benzodiazepine with anxiolytic effects. It is a metabolite of the designer drug diclazepam that can be detected in either the serum or urine. Delorazepam can also be produced by enzymatic treatment of lorazepam with β-glucuronidase. It is indicated for the treatment of anxiety, tension and other somatic or psychiatric manifestations associated with anxiety syndrome, insomnia. The side effects and precautions for use of delorazepam are the same as for all benzodiazepines, in particular as regards the development of dependence (mental and physical) and tolerance. Prolonged use may lead to difficulties remembering recent names and events (anterograde amnesia). It has been approved for marketing in Italy.

Approval Year

PubMed

Title	Date	PubMed
Participation of GABAergic mechanisms in the hypotensive and bradycardic effects of clonidine: experimental study in conscious normotensive and hypertensive rats.	1987 Oct	3683766
Psychotic affective disorder after nicotine withdrawal.	1994 Mar	8109663
SPME-LC with UV detection to study delorazepam-serum albumin interactions.	2002 Jul 31	12093523
Determination of delorazepam in urine by solid-phase microextraction coupled to high performance liquid chromatography.	2002 Jun 1	12039639
An observational study in psychiatric acute patients admitted to General Hospital Psychiatric Wards in Italy.	2007 Jan 27	17257438
GABA(A) receptors in normal development and seizures: friends or foes?	2008 Mar	19305785
Quantification of chlordesmethyldiazepam by liquid chromatography-tandem mass spectrometry: application to a cloxazolam bioequivalence study.	2009 Dec	19488979
Treatment with aripiprazole and topiramate in an obese subject with borderline personality disorder, obsessive-compulsive symptoms and bulimia nervosa: a case report.	2009 Jul 23	19829941

Patents

Sample Use Guides

In Vivo Use Guide

Anxiety: 1 tablet of 0.5-1 mg 2-3 times a day Insomnia: 1 tablet of 0.5-1-2 mg in the evening before bedtime.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:32:01 GMT 2023` Edited by `admin` on `Fri Dec 15 15:32:01 GMT 2023`
Record UNII	O91W32476G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DELORAZEPAM

Official Name

English

DADUMIR

Brand Name

English

CHLORDESMETHYLDIAZEPAM

Common Name

English

7-CHLORO-5-(O-CHLOROPHENYL)-1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE

Common Name

English

DELORAZEPAM [MART.]

Common Name

English

delorazepam [INN]

Common Name

English

NSC-169895

Code

English

Delorazepam [WHO-DD]

Common Name

English

Classification Tree Code System Code

DEA NO.

2754